Forte Biosciences (FBRX) Net Cash Flow (2016 - 2026)

Forte Biosciences (FBRX) has reported Net Cash Flow for 11 consecutive years, with -$18.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 179.31% year-over-year to -$18.7 million; the TTM figure through Mar 2026 stood at $12.4 million (down 19.82% YoY), while the FY2025 annual figure was $54.7 million, up 467.55% from the prior year.
• Net Cash Flow fell to -$18.7 million in Q1 2026 per FBRX's latest filing, from -$16.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $60.3 million in Q2 2025 and bottomed at -$18.7 million in Q1 2026.
• Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of -$5.2 million in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 1113.93% in 2025 and fell as far as 380.14% in 2025.
• Forte Biosciences' Net Cash Flow stood at -$2.9 million in 2022, then slumped by 207.33% to -$9.1 million in 2023, then jumped by 164.91% to $5.9 million in 2024, then plunged by 380.14% to -$16.5 million in 2025, then dropped by 13.66% to -$18.7 million in 2026.
• Business Quant data shows FBRX's Net Cash Flow at -$18.7 million in Q1 2026, -$16.5 million in Q4 2025, and -$12.7 million in Q3 2025.